EFERTUS healthcare s.r.o.
- Address
- Vinicni 4049/235, Zidenice, 615 00 Brno, Czechia
Cardiovascular Diseases
At EFERTUS healthcare s.r.o. in Brno, clinical research in cardiovascular medicine focuses on major heart and blood vessel conditions, with attention to reducing serious complications and improving patient outcomes.
- Atherosclerotic cardiovascular disease
- Heart failure
- Cardiovascular disease risk
These studies are designed to evaluate new treatment approaches and measure whether they can lower the risk of major cardiovascular events, ease symptoms, and support better day-to-day function.
Nutritional and Metabolic Diseases
Research in nutritional and metabolic disorders at this site addresses conditions linked to weight, blood sugar, and metabolic health, often overlapping with cardiovascular risk.
- Type 2 diabetes
- Obesity
- Overweight
- Overweight or obesity
The trials aim to test new therapies and compare their effectiveness in improving metabolic control while also looking at possible benefits for long-term heart health.
Cardiometabolic Risk and Related Conditions
This research area brings together cardiometabolic disease and associated complications, including kidney involvement and elevated lipoprotein(a), reflecting a broader effort to understand interconnected health risks.
- Elevated lp(a)
- Chronic kidney disease
- Cardiovascular diseases
Ongoing studies are evaluating whether new treatments can reduce major adverse events, improve clinical outcomes, and offer more effective options for people with complex, overlapping diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Pfizer Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in EFERTUS healthcare s.r.o.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| J2A-MC-GZGS: A Phase 3, Open-Label Study of Once Daily Orforglipron Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4) | Eli Lilly & Co. | Phase III | Not Recruiting | Aug 2023 | Mar 2026 |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Canagliflozin | 1 | Unknown | 2023-08-02 | 2023-08-02 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.